SHERIDAN, WYOMING - April 14, 2026 - Medidata Solutions has received the top "Luminary" placement in Everest Group's 2026 review of life sciences technology platforms, with the assessment citing the company's market performance, partnership portfolio, and AI solution maturity. The recognition arrives alongside two concrete partnership expansions: a deepened agreement with The Menarini Group to deploy Medidata's Study Build AI technology across a global oncology pipeline, and a new integration with CRIO connecting more than 2,500 research sites worldwide. Together, these developments mark a period of deliberate platform consolidation and AI-scale deployment for one of the most broadly deployed clinical data infrastructure providers in the life sciences sector.
Business Impact
The Everest Group Luminary designation, the highest awarded in this category, reflects demonstrated adoption across sponsor types, geographies, and therapeutic areas. Medidata's platform spans Patient, Data, and Study Experiences and has been used in FDA novel drug approvals as recently as 2025. The expanded Menarini partnership applies Medidata's Study Build AI specifically to accelerate the pharmaceutical group's global oncology pipeline, targeting faster study configuration and reduced setup timelines. The CRIO integration extends seamless connectivity to more than 2,500 research sites, reducing operational friction at the point of study execution where delays most commonly accumulate.
AI and Platform Development
At NEXT New York, Medidata showcased AI Companions and what it characterizes as Orchestrated Intelligence, positioning AI as a workflow-embedded capability across the trial lifecycle rather than a standalone feature. The platform supports a range of AI-enabled applications, including automated medical coding via Coder+, risk-based source data verification through Targeted SDV, endpoint adjudication via Adjudicate, and protocol optimization tools. A partnership with Anthropic is listed among Medidata's active technology collaborations, suggesting further development of large language model applications within the clinical context. The Synthetic Control Arm® product has also achieved a regulatory first: the FDA accepted the first Phase III registration trial design in which the majority of patients were sourced from an external control arm, a milestone documented in a glioblastoma trial.
Operational Evidence
Deployments across sponsor and CRO segments provide measurable reference points. A mid-sized sponsor achieved a 50% increase in site count for a rare disease clinical trial using the Medidata platform. A global CRO completed study setup in four to six weeks. At ICON, implementation of Clinical Data Studio aligned clinical risk management, data management, and medical review teams. Luke Gregory, Senior Director, Clinical Systems Operations at ICON, noted: "There are cost reductions, and we're able to expedite timelines. We're getting listings live at first-patient-in. We're getting triangular review done-we're getting manual review done faster." PROMETRIKA's deployment of Medidata's RTSM solution produced a similar assessment of platform integration value, with President and CEO Miganush Stepanians stating: "There is great benefit in having everything sit on the same platform."
Key facts:
- Everest Group ranked Medidata the top "Luminary" in its 2026 review, citing market performance, partnerships, and AI maturity
- Medidata expanded its partnership with The Menarini Group to deploy Study Build AI across the group's global oncology pipeline
- Integration with CRIO now connects more than 2,500 global research sites to the Medidata platform
- A mid-sized sponsor recorded a 50% increase in site count for a rare disease trial on Medidata's platform
- The FDA accepted the first Phase III registration trial design using Medidata's Synthetic Control Arm®, with the majority of patients sourced from an external control arm